Link: https://youtu.be/u4VTFb4awrQ

Duration: 147 min

Short Summary

Host Andrew Huberman interviews Dr. Alex Marson, a medical doctor and scientist at the University of California, San Francisco, who later moved his lab to the Gladstone Institutes. The episode explores the reprogramming of the immune system through CAR T-cell therapy and CRISPR technology to cure cancers and address autoimmune diseases.

Key Quotes

1. "We're living in this amazing moment of biology where we can put a gene that encodes something on the surface of tea cells that will make them programmed to search and destroy for cancer cells." (00:00:00)
2. "I think that we should have a line in the sand where we do not introduce genetic edits that will be passed on to the next generation." (00:22:20)

Detailed Summary

Episode Summary: Reprogramming the Immune System and Genetic Engineering

Interviewee Background and Scope

• Host Andrew Huberman interviews Dr. Alex Marson, a medical doctor and scientist at the University of California, San Francisco, who transitioned his research focus to the Gladstone Institutes in 2020.
• Dr. Marson leads a lab of approximately 30 people where research ideas emerge from graduate students and postdocs, focusing on developing methods to reprogram the immune system for cancer cures.

CAR T-Cell Therapy and CRISPR Innovations

• Chimeric antigen receptor (CAR) T cells are engineered with surface genes to search and destroy cancer cells, representing a breakthrough not found in nature; the first patient was eight-year-old Emily Whitehead treated in 2012 using lentiviruses.
• The target protein for early CAR-T therapy was CD19, found on B-cell leukemias and lymphomas, while current clinical trials utilize CRISPR-engineered cells to target solid tumors.
• Arsenal Biosciences is currently in its third clinical trial for solid tumors, editing patient cells with up to 10,000 nucleotides of DNA code to industrialize this technology.

Mechanisms of Genetic Engineering and Delivery

• CRISPR functions as an enzyme capable of cutting any DNA sequence, allowing scientists to paste in new features like CAR sequences, building on the 2012 paper by Emmanuel Charpentier and Jennifer Doudna.
• Emerging trends involve delivering CRISPR directly into the body using lipid nanoparticles (LNPs), which were successfully used to inject over a billion people with mRNA vaccines.
• A University of Pennsylvania company developed lipid nanoparticles containing proteins that recognize T-cell surfaces to deliver mRNA and encode CARs without removing cells from the bloodstream.

Immune System Mechanics and Autoimmunity

• T cells coordinate the immune response by generating unique, random receptors in the thymus that are not inherited in the germline DNA, distinguishing them from the innate immune system.
• Autoimmune diseases such as rheumatoid arthritis, type 1 diabetes, and multiple sclerosis arise when T-cells and B-cells react to self-antigens due to failures in normal checks.
• New engineered T-cell trials are showing incredible responses for lupus, childhood diabetes, and rheumatoid arthritis by engineering T-cells to eliminate B cells.

Environmental Factors and Metabolic Health

• Cancer risks are influenced by environmental factors including charred meats, UV light, and toxins like pesticides, alongside genetic predispositions such as BRCA mutations.
• A study by postdoc Sager Bapat found that mice on a high-fat diet exhibited a qualitative difference in immune response, where obesity worsened inflammation despite antibody treatments for severe allergies.

Ethical Considerations and Future Directions

• A controversial CRISPR-Cas9 experiment in China involved modifying two twins to delete the CCR5 gene for HIV resistance, resulting in house arrest for the researcher due to concerns over informed consent.
• Dr. Marson recommends a "line in the sand" where genetic edits are not introduced if they will be passed on to the next generation, distinguishing these from somatic edits in immune cells.
• Bispecific T-cell engagers (BiTEs) are two-headed antibodies recognizing cancer cells and T-cells simultaneously, a concept trademarked by Amgen and now enhanced by AI models.